Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
This article was originally published in The Pink Sheet Daily
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
You may also be interested in...
Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.